Assembly biosciences reports interim phase 1a data from clinical study of oral entry inhibitor candidate abi-6250 for hepatitis delta virus

– data to date in single- and multiple-ascending dose cohorts of healthy participants demonstrate a four-day half-life for abi-6250, supporting target daily oral dosing profile and dose-dependent elevations in biomarker of target engagement – – further pharmacological assessment to be conducted in parallel with phase 2 preparation – south san francisco, calif., aug. 06, 2025 (globe newswire) -- assembly biosciences, inc. (nasdaq: asmb), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced interim data from several cohorts from the ongoing phase 1a clinical trial of abi-6250, the company's orally bioavailable, small molecule hepatitis delta virus (hdv) entry inhibitor candidate.
ASMB Ratings Summary
ASMB Quant Ranking